2月8日，信达生物宣布与礼来制药达成战略合作，共同推进肿瘤及免疫领域创新药物的全球研发。根据 合作协议，信达生物将主导相关项目从药物发现至中国临床概念验证（二期临床试验完成）的研发工 作。礼来获得相关项目在大中华区以外的全球独家开发与商业化许可，信达生物保留相关项目在大中华 区的全部权利。根据协议条款，信达生物将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信 达生物还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外，信达生物有权就各 产品在大中华区以外的净销售额获得梯度的销售分成。 ...

Core Insights - Innovent Biologics has signed a deal with Eli Lilly to jointly develop experimental medicines targeting cancer and immune-related diseases, marking the continuation of a partnership that has lasted over a decade [4] Company Developments - The new agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, indicating a strong and ongoing relationship in the biopharmaceutical sector [4]

每经AI快讯，2月8日，信达生物在港交所发布公告，公司连同其附属公司信达生物制药(苏州)有限公 司、Fortvita Biologics (Singapore) Pte. Ltd, Fortvita Biologics Inc.及Fortvita Biologics (USA), Inc.与礼来公 司达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。本次协议为双方第七次合作，进一步 深化了双方长期且富有成效的合作伙伴关系，携手为全球患者带来创新药物。这一独特的合作架构也为 公司打造了全新的合作模式，加速公司创新研发管线的全球化开发进程。 ...

Core Insights - Company has entered into a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, marking the seventh partnership between the two entities [1] - The collaboration aims to leverage complementary strengths to accelerate the global development of innovative drugs, with the company leading projects from drug discovery to clinical concept validation in China [1] - Eli Lilly will obtain exclusive global development and commercialization rights outside Greater China, while the company retains all rights within Greater China [1] Financial Terms - The agreement includes an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future milestones [2] - The company is entitled to a tiered sales share from net sales of each product outside Greater China [2] Collaboration Model - This partnership breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates the company's flexible drug discovery and early development capabilities with Eli Lilly's extensive global presence [2] - The collaboration underscores the company's core R&D capabilities and aims to expedite the translation of scientific discoveries into globally impactful medical solutions [2]

根据协定条款，公司将获得3.5亿美元首付款;在达成后续特定里程碑事件后，公司还有资格获得总额最 高约85亿美元的研发、监管及商业化里程碑付款。此外，公司有权就各产品在大中华区以外的净销售额 获得梯度的销售分成。 智通财经APP讯，信达生物(01801)发布公告，公司连同其附属公司信达生物制药(苏州)有限公司、 Fortvita Biologics (Singapore) Pte. Ltd, Fortvita Biologics Inc.及Fortvita Biologics (USA), Inc.与礼来公司达 成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。本次协议为双方第七次合作，进一步深化 了双方长期且富有成效的合作伙伴关系，携手为全球患者带来创新药物。这一独特的合作架构也为公司 打造了全新的合作模式，加速公司创新研发管线的全球化开发进程。 根据合作协定，双方将发挥互补优势，加快推进创新药物的全球研发工作。公司依托自身成熟的抗体技 术平台及高效的临床能力，将主导相关项目从药物发现至中国临床概念验证(二期临床试验完成)的研发 工作。根据协定，礼来获得相关项目在大中华区以外的全球独家开发与商业化许可，公 ...

Core Viewpoint - The company has entered into a strategic collaboration with Eli Lilly to advance the global development of innovative drugs in the oncology and immunology fields, which includes significant financial incentives and revenue-sharing opportunities [1] Group 1: Strategic Collaboration - The company, along with its subsidiaries, has formed a partnership with Eli Lilly to enhance drug development in oncology and immunology [1] - The agreement includes an upfront payment of $350 million to the company [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] Group 2: Revenue Sharing - The company will have the right to receive a tiered sales share from net sales outside of Greater China for each product developed under this collaboration [1]

Core Viewpoint - The company has entered into a strategic collaboration with Eli Lilly to advance global research and development of innovative drugs in the oncology and immunology fields, which includes significant financial incentives and revenue-sharing opportunities [1] Group 1: Financial Terms - The company will receive an upfront payment of $350 million as part of the agreement [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] - The company will also have the right to receive a tiered sales share based on net sales outside of Greater China for each product [1]

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, marking their seventh partnership and enhancing their long-term relationship [1][2]. Group 1: Strategic Collaboration - Innovent Biologics, along with its subsidiaries, has entered into a strategic collaboration with Eli Lilly to promote global R&D of innovative drugs in oncology and immunology [1]. - The agreement allows Innovent to leverage its mature antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept validation in China [1][2]. - Eli Lilly will obtain exclusive global development and commercialization rights for the projects outside Greater China, while Innovent retains all rights within Greater China [1]. Group 2: Financial Terms - Innovent will receive an upfront payment of $350 million, with the potential to earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [2]. - The company will also be entitled to a tiered sales share based on net sales of each product outside Greater China [2]. Group 3: Innovation Ecosystem - This collaboration breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates Innovent's flexible drug discovery and early development capabilities with Eli Lilly's extensive global presence [2]. - The partnership underscores Innovent's core R&D strength and aims to accelerate the translation of scientific discoveries into impactful medical solutions for global patients [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1801） 內幕消息公告 與禮來製藥達成全球戰略合作 推進腫瘤及免疫領域的新藥開發 信達生物製藥 INNOVENT BIOLOGICS, INC. 本公告由信達生物製藥（「本公司」及「信達」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09條及香港法例第571章證券及期貨條例第XIVA部作 出。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司連同其附屬公司信達生物 製藥（蘇州）有限公司、Fortvita Biologics (Singapore) Pte. Ltd, Fortvita Biologics Inc.及Fortvita Biologics (USA), Inc.與禮來公司（「禮來」）達成戰略合作，攜手推 進腫瘤及免疫領域創新藥物的全球研發。本次協議為雙方第七次合作，進一步深 化了雙方長期且富有成效的合作夥伴關係，攜手為 ...

Core Insights - Innovent Biologics has announced a strategic collaboration with Eli Lilly to advance novel medicines in oncology and immunology, marking their seventh partnership and enhancing their long-term relationship [1][2] Collaboration Details - The collaboration will leverage the complementary strengths of both companies to accelerate the global development of new medicines, with Innovent leading the development in China and Lilly obtaining exclusive rights outside Greater China [2] - Innovent will receive a $350 million upfront payment and could earn up to approximately $8.5 billion in milestone payments based on future achievements, along with tiered royalties on net sales outside Greater China [3] Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, having launched 16 products and currently having multiple assets in different stages of clinical trials [4] - The company partners with over 30 global healthcare firms, including Eli Lilly, to enhance its research and development capabilities [4]